Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vanda Pharmaceuticals Inc. - Common Stock
(NQ:
VNDA
)
7.470
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vanda Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark
↗
August 18, 2025
Via
Stocktwits
Vanda (VNDA) Q2 Revenue Rises 4%
↗
August 01, 2025
Via
The Motley Fool
Topics
Intellectual Property
Earnings Scheduled For July 31, 2025
↗
July 31, 2025
Via
Benzinga
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
A Glimpse of Vanda Pharma's Earnings Potential
↗
May 06, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
April 23, 2025
Via
Benzinga
Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals
↗
April 01, 2025
Via
Benzinga
The Analyst Verdict: Vanda Pharma In The Eyes Of 5 Experts
↗
February 18, 2025
Via
Benzinga
Earnings Scheduled For February 13, 2025
↗
February 13, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts
↗
January 28, 2025
Via
Benzinga
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
February 03, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate
↗
January 16, 2025
FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the agency's review process.
Via
Benzinga
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
December 16, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
↗
November 01, 2024
HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology.
Via
Benzinga
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
↗
September 19, 2024
A regulator's decision drained the market's enthusiasm for the company.
Via
The Motley Fool
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies
↗
September 19, 2024
The FDA rejected Vanda Pharmaceuticals' new drug application for tradipitant to treat gastroparesis, citing the need for more studies despite delays in its review process. Vanda argues the drug meets...
Via
Benzinga
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
August 06, 2024
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves...
Via
PressReach
What's Going On With Vanda Pharmaceuticals Shares Today?
↗
June 27, 2024
Vanda Pharmaceuticals shares decline as Future Pak withdraws acquisition offer following Vanda's rejection and lack of response.
Via
Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
June 20, 2024
Via
Benzinga
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
↗
June 20, 2024
Via
Benzinga
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
June 20, 2024
Via
Benzinga
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
↗
June 13, 2024
Via
Benzinga
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
June 10, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
↗
June 06, 2024
Via
Benzinga
Topics
Stocks
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
June 06, 2024
Via
Benzinga
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
↗
June 06, 2024
Via
Benzinga
Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal
↗
June 06, 2024
Cycle Pharmaceuticals wants to acquire Vanda Pharmaceuticals for $8 per share, or $466 million. Cycle focuses on rare neurological conditions.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
June 06, 2024
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!
Via
InvestorPlace
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
May 09, 2024
Via
Benzinga
VNDA Stock Earnings: Vanda Pharma Misses EPS, Misses Revenue for Q1 2024
↗
May 08, 2024
VNDA stock results show that Vanda Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
